MaxCyte (NASDAQ:MXCT) Stock Rating Upgraded by Wall Street Zen

MaxCyte (NASDAQ:MXCT) was upgraded by research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Sunday.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of MaxCyte in a research report on Monday, December 29th. One equities research analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $6.00.

MaxCyte Stock Performance

NASDAQ MXCT opened at $0.82 on Friday. The business’s 50 day moving average price is $0.97 and its 200-day moving average price is $1.36. The company has a market cap of $87.45 million, a P/E ratio of -1.86 and a beta of 1.22. MaxCyte has a fifty-two week low of $0.64 and a fifty-two week high of $3.33.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the stock. Prudential Financial Inc. bought a new stake in MaxCyte during the second quarter valued at about $26,000. State of Wyoming bought a new position in MaxCyte in the second quarter worth about $38,000. Dynamic Technology Lab Private Ltd bought a new position in MaxCyte in the second quarter worth about $40,000. Kwmg LLC lifted its position in shares of MaxCyte by 75.8% during the third quarter. Kwmg LLC now owns 25,833 shares of the company’s stock valued at $41,000 after buying an additional 11,135 shares during the last quarter. Finally, Jain Global LLC purchased a new stake in shares of MaxCyte during the fourth quarter valued at about $45,000. 68.81% of the stock is owned by institutional investors.

About MaxCyte

MaxCyte, Inc (NASDAQ: MXCT) is a clinical‐stage cell therapy platform company that develops and commercializes proprietary flow electroporation technology for the delivery of macromolecules into living cells. The company’s instruments and consumables are designed to support research, preclinical development and clinical‐scale manufacturing of cell therapies across a variety of modalities, including engineered T cells, natural killer (NK) cells and induced pluripotent stem cell (iPSC) therapies.